<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1558">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140876</url>
  </required_header>
  <id_info>
    <org_study_id>20190578</org_study_id>
    <secondary_id>R01DA049843</secondary_id>
    <nct_id>NCT05140876</nct_id>
  </id_info>
  <brief_title>Supporting Treatment Adherence for Resilience and Thriving (START)</brief_title>
  <acronym>START</acronym>
  <official_title>Supporting Treatment Adherence for Resilience and Thriving</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II randomized controlled trial is testing the efficacy of a cell phone application&#xD;
      called START for helping men who use stimulants like methamphetamine to get the most out of&#xD;
      their HIV treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2022</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV viral load levels</measure>
    <time_frame>6 Months</time_frame>
    <description>As assessed from dried blood spot samples collected by participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV viral load</measure>
    <time_frame>12 Months</time_frame>
    <description>As assessed from dried blood spot samples collected by participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Reported Stimulant Use Severity</measure>
    <time_frame>12 Months</time_frame>
    <description>The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) provides validated composite scores indexing the severity of cocaine and amphetamine use (Mild = 0-3; Moderate = 4-26; Severe = 27 or greater).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Reported Anti-Retroviral Therapy (ART) Adherence</measure>
    <time_frame>12 Months</time_frame>
    <description>Participants will rate on a visual analogue scale the percentage of ART medications that they took in the past 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Affect</measure>
    <time_frame>12 Months</time_frame>
    <description>Mean positive affect score as measured by the modified Differential Emotions Scale (Range 0-104) with higher scores being indicative of higher positive affect.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Adherence, Medication</condition>
  <condition>HIV-1-infection</condition>
  <condition>Stimulant Use</condition>
  <arm_group>
    <arm_group_label>START mHealth Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive the START mHealth intervention will have access to the mHealth application for 6 months following randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Website referrals</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in this condition will receive no intervention and will have access to a website with resources related to substance use disorder treatment and HIV treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>START mHealth Intervention</intervention_name>
    <description>The START mHealth intervention is a mobile application that will be downloaded by participants through their mobile phones. The application targets information, motivation, and behavioral skills relevant to ART adherence. Participants will have access to this application for 6 months.</description>
    <arm_group_label>START mHealth Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Assigned male at birth;&#xD;
&#xD;
          2. Identifies as male;&#xD;
&#xD;
          3. Age 18 or older;&#xD;
&#xD;
          4. reads and speaks English;&#xD;
&#xD;
          5. Continental US residency;&#xD;
&#xD;
          6. Reports any anal sex with a man in the past year;&#xD;
&#xD;
          7. Currently has an active Antiretroviral Therapy (ART) prescription and reports less&#xD;
             than excellent ART adherence (past 30 days);&#xD;
&#xD;
          8. Screens positive for a moderate or severe stimulant use disorder with an abbreviated&#xD;
             version of the National Institute on Drug Abuse (NIDA)-modified Alcohol, Smoking and&#xD;
             Substance. Involvement Screening Test (ASSIST);&#xD;
&#xD;
          9. Has an iPhone or Android smartphone;&#xD;
&#xD;
         10. Is willing to participate in an mHealth intervention;&#xD;
&#xD;
         11. Is willing to provide a Dried Blood Spot (DBS) specimen for viral load testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HIV-negative or never tested for HIV;&#xD;
&#xD;
          2. HIV-positive men without a current ART prescription;&#xD;
&#xD;
          3. Does not return a viable DBS specimen at baseline for viral load testing&#xD;
&#xD;
          4. Not a sexual minority man&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Identifies as male</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam W Carrico, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adam W Carrico, PhD</last_name>
    <phone>305-243-6947</phone>
    <email>a.carrico@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of MIami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Adam W Carrico, PhD</last_name>
      <phone>305-243-6947</phone>
      <email>a.carrico@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Adam W Carrico, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Adam Carrico</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

